Annexon Inc. stock saw a solid bump recently, with shares jumping nearly 9.4% to hit $5.42 on the NASDAQ. Trading under the ticker ANNX, the clinical-stage biopharmaceutical company now boasts a market cap of roughly $808.6 million. Investors seem relatively optimistic despite the day’s volatile range between $5.24 and $6.10, especially considering the stock has navigated a massive 52-week spread of $1.29 to $7.18. The trading volume was right around the daily average at 2.48 million shares, reflecting steady market interest as the company updates its investors on both its clinical progress and financial standing.
Targeting Complement-Mediated Disorders
Operating squarely within the healthcare and biotechnology sector, Annexon is focused on developing novel therapies for classical complement-mediated disorders. These complex conditions, which can severely impact the body, brain, and eyes, are generally triggered by an abnormal activation of the C1q protein. To combat this, the company has built a specialized technology platform designed to block C1q activity right at the source, aiming to halt the entire classical complement pathway.
Their growing pipeline includes several distinct product candidates tailored for specific medical needs. For instance, ANX005 targets autoimmune and neurodegenerative disorders, while ANX007 is aimed specifically at neurodegenerative ophthalmic conditions. Furthermore, they are advancing an oral small molecule known as ANX1502, alongside ANX009, which is currently being developed to tackle systemic autoimmune diseases.
Widening Annual Losses Amid Q4 Improvement
Alongside the recent market activity, Annexon just released its financial results for the fourth quarter and the full fiscal year ending December 31, 2025. Looking at the broader picture, the company reported a widening net loss for the entire year, coming in at $206.69 million compared to $138.2 million during the previous year. This translates to a basic and diluted loss per share from continuing operations of $1.34, down from $1.01 a year earlier.
However, the fourth quarter actually showed a slight year-over-year improvement. Net loss for the final three months of 2025 narrowed down to $48.26 million, edging past the $48.59 million loss reported in the same period last year. Consequently, both basic and diluted loss per share for the quarter sat at $0.28. This marks a noticeable step up from the $0.33 loss per share recorded in the prior year’s fourth quarter, perhaps giving investors a reason to rally behind the stock.